about
Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.Reformulating cyclosporine A (CsA): More than just a life cycle management strategy.Development and validation of a HPLC method for the determination of cyclosporine a in new bioadhesive nanoparticles for oral administrationHematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice.Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity.High-performance liquid-chromatographic determination of rifampicin in plasma and tissues.Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography. Application to particulate drug delivery systems.Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease.Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation.Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studiesPharmacokinetic profiles of prazepam and 14C-prazepam in ratDetermination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysisHigh-performance liquid chromatographic determination of amphotericin B in plasma and tissue. Application to pharmacokinetic and tissue distribution studies in rats
P50
Q36208560-B83234F4-EA8B-4030-BEAB-7D8D53C907EAQ38717568-0A1FE8FD-3C8B-4D60-AD3C-FB1231FF50E6Q39671883-1FF16641-BBC5-48A2-9264-E50B3E2FF838Q40556860-3A556E4A-282D-4039-BFB7-15CB2E828168Q44004231-C96C4E65-7DA8-404F-BCEE-78F7261F5F99Q44329149-3E655A6D-83BB-403D-A539-7C80992F0AF7Q44825792-BBCFB6D8-2199-4BCB-A6C9-5A569D87BF19Q44825795-42A14DB3-76B7-44B4-A684-0919F4B910F8Q50870110-0605AB99-6CB0-47A5-804E-704954524375Q53177025-A7B2F693-290C-4A5A-B82E-056F3E1866F2Q60488252-15FD510E-2CEE-4C8D-BF8D-E46C10A143F2Q67894186-1907F203-F011-47CD-A69F-2100F9BE512DQ71750197-DDB48FBC-7100-4B2A-A02F-A51DFBBE018DQ77441119-7162F992-7CF3-42EF-A0F9-2599FDAFB9F4
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Mª del Carmen Dios-Viéitez
@ast
Mª del Carmen Dios-Viéitez
@en
Mª del Carmen Dios-Viéitez
@es
Mª del Carmen Dios-Viéitez
@nl
type
label
Mª del Carmen Dios-Viéitez
@ast
Mª del Carmen Dios-Viéitez
@en
Mª del Carmen Dios-Viéitez
@es
Mª del Carmen Dios-Viéitez
@nl
prefLabel
Mª del Carmen Dios-Viéitez
@ast
Mª del Carmen Dios-Viéitez
@en
Mª del Carmen Dios-Viéitez
@es
Mª del Carmen Dios-Viéitez
@nl
P106
P1153
6602348454
P31
P496
0000-0003-2916-6306